ESMO 2014 - Gastrointestinal and Head & Neck Cancer

FOLFOXIRI plus Bevacizumab or Anti-EGFR Antibodies in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

Conference Correspondent - ESMO 2014 - Gastrointestinal and Head & Neck Cancer

Monoclonal antibodies (MoAbs) targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) in combination with first-line doublet chemotherapy have demonstrated considerable clinical activity in metastatic colorectal cancer (mCRC). The fluoropyrimidine, folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) regimen [ Read More ]

Subgroup Analysis of CRYSTAL: FOLFIRI plus Cetuximab in Liver-Limited or Non–Liver-Limited Disease

Conference Correspondent - ESMO 2014 - Gastrointestinal and Head & Neck Cancer

The CRYSTAL study demonstrated that the addition of cetuximab to first-line chemotherapy significantly improved clinical outcomes, specifically for patients with RAS wild-type metastatic colorectal cancer (mCRC). Previous retrospective studies have shown that cetuximab plus chemotherapy provided clinical benefit for patients [ Read More ]